The Center for Psychedelic Psychotherapy and Trauma Research will be led by Rachel Yehuda, PhD, Professor of Neuroscience and Psychiatry at the Icahn School of Medicine. The Icahn School of Medicine at the Mount Sinai Health System in New York announced the launch of a new center for psychedelics research. New York’s Mount Sinai Launches Psychedelics Research Center 1, the Oregon Health Authority will work with the Oregon Psilocybin Advisory Board to develop the program. The measure included a two-year period to develop and implement the program, via which patients over the age of 21 will be allowed to buy, possess and use psilocybin under the supervision of trained facilitators, while manufacture, delivery and administration of the drug will be allowed at licensed facilities. It sets up a program that regulates psilocybin, the active psychedelic ingredient in “magic mushrooms.” ( h/t The Source Weekly). Oregon’s 2021 to 2023 budget included $5.6 million to begin implementing Measure 109, a legislation approved in the November ballot. Oregon Includes Psilocybin Program In 2021 Budget The company is expecting to collaborate as a contract research organization for other companies or research institutions in the sector through its clinical research arm. “There's a clinic network and there's a clinical research facility which is also turning into a network.” “In short, there's two cores for our business,” Novamind CEO Yaron Conforti said. In July, Novamind acquired the Utah-based Cedar network for CA$3.05 million (CA$1 million in cash and CA$2.05 million in Novamind shares).Ĭedar is known for offering innovative and alternative neuropsychiatric modalities like transcranial magnetic stimulation and ketamine-assisted psychotherapy. The company’s goal is to develop therapeutic protocols in conjunction with other players in the space, as well as offering treatment options for patients through a network of clinics and retreats. In late November, Novamind closed a private placement for CA$10 million ($7.8 million), adding to a total of CA$15.3 million raised since its inception.Īs opposed to other psychedelics companies, Novamind is not building a library of intellectual property around psychedelic molecules. Novamind debuted in the Canadian Securities Exchange on Tuesday under the symbol "NM," through a reverse take-over with Hinterland Metals Inc. “For-profit or non-profit, we are all together in seeking to bring new methods of psychedelic healing to those millions who need it,” MAPS founder and executive director Rick Doblin said.Įarlier this week, Field Trip also announced closing a bought deal offering for proceeds of over CA$20 million (approximately $15.7 million). In total, 12 participants will be administered MDMA and 18 caregivers - a parent or partner - will receive non-drug psychotherapy support as part of the study. In July 2020, the Multidisciplinary Association for Psychedelic Studies announced a Phase 2 clinical trial, meant to assess the safety and feasibility of MDMA treatment in anorexia nervosa and binge eating disorder.įield Trip’s Toronto location was selected as one of three sites, others being Vancouver and Denver.
#Novamind map trial
MAPS and Field Trip Team Up To Study MDMA In Eating Disordersįield Trip Health's FTRPF Toronto clinic will serve as a trial location for MAPS’ upcoming study on MDMA-assisted therapy to treat eating disorders. The company is currently developing protocols for a phase II human clinical trial on the same subject, which it expects to present for approval in early 2021. So far, it filed five provisional patent applications claiming the use of psilocybin and other psychedelics as possible treatments. NeonMind’s psychedelics research arm is focused on studying the possible applications of psilocybin in the treatment of eating disorders. In November 2020, NeonMind launched a line of non-psychedelic functional mushroom products available through its own ecommerce store.
0 kommentar(er)
